GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Net Income From Continuing Operations

4basebio (LSE:4BB) Net Income From Continuing Operations : £-6.28 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. 4basebio's net income from continuing operations for the six months ended in Jun. 2023 was £-3.56 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was £-6.28 Mil.

4basebio Net Income From Continuing Operations Historical Data

The historical data trend for 4basebio's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Net Income From Continuing Operations Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
-0.42 -0.72 -3.24 -5.15

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Income From Continuing Operations Get a 7-Day Free Trial -1.65 -1.59 -2.43 -2.72 -3.56

4basebio Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-6.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4basebio (LSE:4BB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Net Income From Continuing Operations
Comparable Companies
LSE:ETX LSE:AREC LSE:OBD LSE:DEST LSE:SBTX LSE:SAR LSE:FUM LSE:TRX LSE:REDX LSE:C4XD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
88Q:Germany
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
Website
https://www.4basebio.com
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (LSE:4BB) Headlines

No Headlines